Our study suggests that the percentage change for second visits relative to baseline of enhanced tumor volume-based imaging metrics of DCE-MRI can quantify heterogeneous changes within the tumor as an indicator of therapy response and improve prediction of PCR as early as the first treatment time point in NAC.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: